Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 4
2019 1
2020 3
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Kudling TV, Clubb JHA, Pakola S, Quixabeira DCA, Lähdeniemi IAK, Heiniö C, Arias V, Havunen R, Cervera-Carrascon V, Santos JM, Sutinen E, Räsänen J, Borenius K, Mäyränpää MI, Aaltonen E, Sorsa S, Hemminki O, Kanerva A, Verschuren EW, Ilonen I, Hemminki A. Kudling TV, et al. Among authors: sorsa s. Oncoimmunology. 2023 Aug 2;12(1):2241710. doi: 10.1080/2162402X.2023.2241710. eCollection 2023. Oncoimmunology. 2023. PMID: 37546696 Free PMC article.
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.
Zafar S, Quixabeira DCA, Kudling TV, Cervera-Carrascon V, Santos JM, Grönberg-Vähä-Koskela S, Zhao F, Aronen P, Heiniö C, Havunen R, Sorsa S, Kanerva A, Hemminki A. Zafar S, et al. Among authors: sorsa s. Cancer Gene Ther. 2021 May;28(5):442-454. doi: 10.1038/s41417-020-00226-z. Epub 2020 Sep 12. Cancer Gene Ther. 2021. PMID: 32920593 Free PMC article.
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A. Havunen R, et al. Among authors: sorsa s. Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21. Mol Ther Oncolytics. 2018. PMID: 30569015 Free PMC article.
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V, Quixabeira DCA, Santos JM, Havunen R, Zafar S, Hemminki O, Heiniö C, Munaro E, Siurala M, Sorsa S, Mirtti T, Järvinen P, Mildh M, Nisen H, Rannikko A, Anttila M, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: sorsa s. Oncoimmunology. 2020 May 22;9(1):1761229. doi: 10.1080/2162402X.2020.1761229. Oncoimmunology. 2020. PMID: 32923123 Free PMC article.
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
Cervera-Carrascon V, Quixabeira DCA, Santos JM, Havunen R, Milenova I, Verhoeff J, Heiniö C, Zafar S, Garcia-Vallejo JJ, van Beusechem VW, de Gruijl TD, Kalervo A, Sorsa S, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Among authors: sorsa s. Front Immunol. 2021 Jul 23;12:706517. doi: 10.3389/fimmu.2021.706517. eCollection 2021. Front Immunol. 2021. PMID: 34367166 Free PMC article.
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA, Kudling TV, Heiniö C, Basnet S, Pakola S, Cervera Carrascón V, Santos JM, Quixabeira DCA, Havunen R, Sorsa S, Zheng V, Salo T, Bäck L, Aro K, Tulokas S, Loimu V, Hemminki A. Clubb JHA, et al. Among authors: sorsa s. Front Immunol. 2022 Mar 7;13:794251. doi: 10.3389/fimmu.2022.794251. eCollection 2022. Front Immunol. 2022. PMID: 35355980 Free PMC article.
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA, Kudling TV, Girych M, Haybout L, Pakola S, Hamdan F, Cervera-Carrascon V, Hemmes A, Grönberg-Vähä-Koskela S, Santos JM, Quixabeira DCA, Basnet S, Heiniö C, Arias V, Jirovec E, Kaptan S, Havunen R, Sorsa S, Erikat A, Schwartz J, Anttila M, Aro K, Viitala T, Vattulainen I, Cerullo V, Kanerva A, Hemminki A. Clubb JHA, et al. Among authors: sorsa s. Front Immunol. 2023 Feb 3;14:1060540. doi: 10.3389/fimmu.2023.1060540. eCollection 2023. Front Immunol. 2023. PMID: 36817448 Free PMC article.
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH. Watanabe K, et al. Among authors: sorsa s. JCI Insight. 2018 Apr 5;3(7):e99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5. JCI Insight. 2018. PMID: 29618658 Free PMC article.
17 results